Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US

Renalytix and Steno are partners in PRIME-CKD (https://www.prime-ckd.com/), funded by the European Union Research and Innovation programme, advancing personalized drug treatment in patients with CKD. For further information, please contact: Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600 Investec Bank plc (Joint Broker) Tel: 020 7597 4000 Gary Clarence / Shalin Bhamra CapComm Partners Peter DeNardo Tel: 415-389-6400 or investors@renalytix.com Steno Diabetes Center Forward-Looking Statements This ...